Matairesinol
Compiled from published pharmacological and botanical literature. Not independently verified by Herbuno. Spotted an error or have a correction? Flag it below →
| Chemical Class | Dibenzylbutyrolactone lignan (plant lignan / phytoestrogen precursor) |
| Molecular Formula / CAS | C₂₀H₂₂O₆ · CAS 580-72-3 |
| Primary Botanical Source(s) | Flaxseed (Linum usitatissimum), sesame seed (Sesamum indicum), whole grains, various conifers |
| Plant Part | Seed (flax, sesame); bark/needles in coniferous sources |
| Typical Content | A minor lignan fraction — roughly 500–3,300 µg/100g in flaxseed, well below secoisolariciresinol (SDG), the dominant flax lignan |
| Solubility / Format | Water-dispersible within whole-seed and defatted seed-meal matrices; not isolated as a standalone extract at commercial scale |
| Sourcing Status | Product-pending — present in existing flax and sesame seed extracts, but not the standardisation marker for any current Herbuno product |
| Buy from Herbuno | Availability on request — contact Herbuno for a formulation quote |
Name origin: Matairesinol takes its name from matairesi, the Māori term for the New Zealand conifer Podocarpus totara, from whose heartwood the compound was first isolated by wood chemists studying durable timber extractives long before its role in human nutrition was recognised. Traditional use: Matairesinol itself carries no dedicated ethnobotanical history — it was never used as an isolated preparation — but the seeds that carry it, flax and sesame, have millennia of documented use across Mediterranean, Middle Eastern and South Asian food and medicinal traditions, valued long before their lignan content was chemically understood. Research trajectory: Interest in matairesinol accelerated once it was identified, alongside secoisolariciresinol, as one of the first two plant lignans shown to convert into the mammalian “enterolignans” enterodiol and enterolactone via colonic bacterial metabolism, placing it at the origin of the modern phytoestrogen research field; more recent work has shifted toward matairesinol’s own direct anticancer and immunomodulatory activity in cell models, independent of its enterolignan conversion. Commercial source: No supplier markets a matairesinol-standardised extract at scale; it is present as a minor, non-standardised constituent within whole flaxseed and sesame seed preparations, where it typically contributes a small fraction of total lignan content relative to the dominant marker compounds of each seed.
Evidence for Matairesinol Applications
Matairesinol belongs to the dibenzylbutyrolactone class of plant lignans and is one of the two original enterolignan precursors identified in the human diet, alongside secoisolariciresinol. Following ingestion, colonic bacteria convert a portion of dietary matairesinol into enterolactone through sequential demethylation, dehydroxylation and dehydrogenation reactions, and the resulting enterolactone is what circulates and exerts weak estrogen-receptor-mediated activity in peripheral tissue. This places matairesinol mechanistically alongside pinoresinol, lariciresinol and secoisolariciresinol as a phytoestrogen precursor rather than a directly estrogenic compound in its native form (Ozdemir et al. 2022). Claim strength: Moderate.
Independent of enterolignan conversion, isolated matairesinol has shown direct antiproliferative activity against several hormone-sensitive and hormone-independent cancer cell lines in laboratory studies. In pancreatic ductal adenocarcinoma cell lines, matairesinol treatment at 20–80 µM induced dose-dependent apoptosis, mitochondrial membrane depolarisation, reactive oxygen species accumulation and suppression of invasive gene expression, with synergistic effects observed when combined with the chemotherapeutic agent 5-fluorouracil (Kim et al. 2022). These findings are confined to in-vitro pancreatic cancer cell models and have not been replicated in human trials. Claim strength: Emerging.
A related line of research has examined matairesinol’s effect on the tumour immune microenvironment rather than direct cytotoxicity. In triple-negative breast cancer cell co-culture models, matairesinol repolarised tumour-associated M2 macrophages toward the pro-inflammatory M1 phenotype, a shift associated with reduced viability of the co-cultured cancer cells and proposed as a candidate mechanism for further investigation in immuno-oncology contexts (et al. 2024). This represents an early-stage mechanistic finding rather than an established therapeutic pathway. Claim strength: Emerging.
Matairesinol has also been studied for skeletal effects distinct from its cancer-related research. In osteoclast differentiation assays, matairesinol suppressed RANKL-induced osteoclastogenesis by interfering with p38/ERK-mediated NFATc1 signalling, reducing both the number of multinucleated osteoclasts formed and the bone-resorptive activity of mature osteoclasts in culture. This anti-osteoclastogenic activity has not been evaluated in animal models of bone density or in human subjects, so its relevance to conditions such as osteoporosis remains speculative pending further study. Claim strength: Emerging.
For formulators, the practical distinction to hold onto is that matairesinol is chemically and functionally distinct from the flaxseed lignan most familiar to the supplement industry, secoisolariciresinol diglucoside (SDG). SDG dominates flaxseed lignan content by a wide margin and is the compound standardised flax lignan extracts are built around; matairesinol is present alongside it as a minor co-constituent. Any claim implying a flax or sesame extract is “matairesinol-standardised” should be treated with the same scrutiny applied to any marker-compound mismatch in botanical sourcing. Claim strength: Moderate.
Dosage & Formulator Specification
No standardised matairesinol extract exists in commercial supply, so there is no established dosing precedent for the isolated compound. Human lignan-intake studies instead report combined dietary lignan intake (secoisolariciresinol plus matairesinol plus their glycosides) typically in the range of 1–3 mg/day from a Western diet, rising to 50–100 mg/day when flaxseed is deliberately supplemented; matairesinol represents a minority fraction of that total in virtually every dietary source studied to date.
Analytical characterisation of matairesinol content in raw material requires liquid chromatography coupled to mass spectrometry (LC-MS/MS) or tandem HPLC methods capable of resolving matairesinol from the structurally similar lariciresinol, pinoresinol and secoisolariciresinol within the same chromatographic run; single-wavelength HPLC without mass confirmation risks co-elution misassignment given how closely these four lignans migrate. Formulators requesting a lignan panel from a supplier should specify individual-lignan quantification rather than accepting an aggregate “total lignan” figure.
Because matairesinol is not isolated commercially, formulation work involving it in practice means working with whole or defatted flaxseed and sesame seed powders or liquid extracts, all carrying matairesinol as one component of a broader lignan matrix. Flaxseed lignans concentrate in the hull rather than the oil, so lignan-rich sourcing intent should specify defatted seed meal or whole-seed powder rather than flaxseed oil, which carries negligible lignan content.
Regulatory positioning for matairesinol-containing material follows standard botanical food-ingredient pathways in most markets, since flax and sesame are established food ingredients with long safety histories; no matairesinol-specific regulatory limit or monograph exists in the major pharmacopoeial or supplement-ingredient databases at this time. Formulators making phytoestrogen-adjacent claims should note that enterolignan conversion is bacteria-dependent and varies substantially between individuals, which limits the precision of any dose-response claim tied to matairesinol content alone.
Frequently Asked Questions — Matairesinol
No. Most flaxseed lignan supplements are standardised to secoisolariciresinol diglucoside (SDG), which is the dominant lignan in flaxseed by a wide margin. Matairesinol is a related but distinct lignan present in smaller amounts alongside SDG, and no commercial extract currently uses it as the standardisation marker.
Colonic bacteria convert a portion of dietary matairesinol into the mammalian lignan enterolactone through a multi-step bacterial metabolism pathway. Enterolactone is the form that circulates in the bloodstream and interacts weakly with estrogen receptors; the conversion efficiency varies considerably between individuals depending on gut microbiome composition.
Laboratory studies have found that isolated matairesinol can induce apoptosis and suppress proliferation in several cancer cell lines, including pancreatic and triple-negative breast cancer models, through mitochondrial and immune-modulatory mechanisms. This evidence is limited to cell-culture studies and has not been tested in human trials, so it should be treated as an early research finding rather than a clinical claim.
Not at this time. Matairesinol is available to formulators only as a minor natural constituent within flax seed or sesame seed extract material, not as an isolated or standardised ingredient. Herbuno can supply flax and sesame seed extracts and discuss lignan-profile analytical options on request.
Related compounds: Pinoresinol, Sesamin